Ovid Therapeutics Inc Asset Resilience Ratio
Ovid Therapeutics Inc asset resilience ratio. Ovid Therapeutics Inc (OVID) has an Asset Resilience Ratio of 45.65% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Ovid Therapeutics Inc (OVID) liquidity interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Ovid Therapeutics Inc (2017–2025)
Asset resilience ratio of Ovid Therapeutics Inc from 2017 to 2025. This chart shows how Ovid Therapeutics Inc's Asset Resilience Ratio has changed over time. Read total liabilities of Ovid Therapeutics Inc for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Ovid Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Ovid Therapeutics Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $105.89 Million | 45.65% |
| Total Liquid Assets | $105.89 Million | 45.65% |
Asset Resilience Insights
- Very High Liquidity: Ovid Therapeutics Inc maintains exceptional liquid asset reserves at 45.65% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Ovid Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Ovid Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Ovid Therapeutics Inc Asset Resilience Ratio by Year (2017–2025)
Ovid Therapeutics Inc asset resilience ratio by year from 2017 to 2025. The table below shows the annual Asset Resilience Ratio data for Ovid Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 37.42% | $56.48 Million | $150.93 Million | +8.37pp |
| 2024-12-31 | 29.05% | $26.77 Million | $92.17 Million | -25.66pp |
| 2023-12-31 | 54.71% | $78.79 Million | $144.03 Million | +0.52pp |
| 2022-12-31 | 54.19% | $84.13 Million | $155.27 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $194.54 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $75.93 Million | -- |
| 2019-12-31 | 43.10% | $34.84 Million | $80.84 Million | +32.58pp |
| 2018-12-31 | 10.52% | $5.01 Million | $47.65 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $89.46 Million | -- |
About Ovid Therapeutics Inc
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human or… Read more